PMID- 32501943
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20230927
IS  - 1536-7355 (Electronic)
IS  - 1076-1608 (Linking)
VI  - 27
IP  - 8
DP  - 2021 Dec 1
TI  - Intravenous Immunoglobulin for Inflammatory Myositis: Experience in a Tertiary 
      Medical Center.
PG  - e616-e621
LID - 10.1097/RHU.0000000000001418 [doi]
AB  - INTRODUCTION: Inflammatory myopathies are treated with glucocorticoids and other 
      immunosuppressive medications. Intravenous immunoglobulin (IVIG) is increasingly 
      used for refractory or severe cases; however, the evidence for their 
      effectiveness is limited. We assessed effectiveness and safety of IVIG when used 
      with other immunomodulatory agents in the treatment of inflammatory myopathies. 
      METHODS: This study reviewed records of patients diagnosed with dermatomyositis 
      or polymyositis and treated with IVIG, from 2009 through 2016 in 1 tertiary 
      medical center. Mixed-effects general linear regression models were applied to 
      determine effectiveness of treatment on muscle strength, creatinine phosphokinase 
      levels, and steroid dosage. RESULTS: Twenty-three patients with 
      dermatomyositis/polymyositis treated with IVIG were followed up for a mean of 31 
      (SD, +/-25) months. During this period, a significant improvement in muscle 
      strength was demonstrated, with a mean increase of 0.92 Medical Research Council 
      scale points (beta = 0.14; confidence interval [CI], 0.136-0.149; p < 0.0001), a 
      significant reduction of creatinine phosphokinase levels and steroid dosage with 
      a mean decrease of 1140 IU/L (beta = -0.274; CI, -0.354 to -0.195; p < 0.0001), and 
      36 mg/d (beta = -0.008; CI, -0.011 to -0.006; p < 0.0001), respectively. Overall, 
      remission was observed in 10 patients (43.5%), and partial remission in 6 
      patients (26%), whereas 1 patient (17%) remained refractory to treatment, and 6 
      patients (27%) were lost to follow-up. CONCLUSIONS: The majority of patients with 
      inflammatory myopathies experienced a clinical and laboratory improvement during 
      IVIG treatment. In addition, a steroid-sparing effect was noticed in most 
      patients. These results encourage the use of IVIG as an alternative treatment 
      option for patients with limited responsiveness to conventional methods.
CI  - Copyright (c) 2020 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Ohad, Maayan
AU  - Ohad M
AD  - From the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.
FAU - Shemer, Asaf
AU  - Shemer A
FAU - Lavie, Inbar
AU  - Lavie I
AD  - From the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv.
FAU - Ozeri, David
AU  - Ozeri D
FAU - Shoenfeld, Yehuda
AU  - Shoenfeld Y
FAU - Kivity, Shaye
AU  - Kivity S
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Rheumatol
JT  - Journal of clinical rheumatology : practical reports on rheumatic & 
      musculoskeletal diseases
JID - 9518034
RN  - 0 (Immunoglobulins, Intravenous)
RN  - 0 (Immunologic Factors)
SB  - IM
MH  - *Dermatomyositis/diagnosis/drug therapy
MH  - Humans
MH  - Immunoglobulins, Intravenous
MH  - Immunologic Factors
MH  - *Myositis/diagnosis/drug therapy
MH  - *Polymyositis/diagnosis/drug therapy
COIS- The authors declare no conflict of interest.
EDAT- 2020/06/06 06:00
MHDA- 2021/11/26 06:00
CRDT- 2020/06/06 06:00
PHST- 2020/06/06 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
PHST- 2020/06/06 06:00 [entrez]
AID - 00124743-202112000-00061 [pii]
AID - 10.1097/RHU.0000000000001418 [doi]
PST - ppublish
SO  - J Clin Rheumatol. 2021 Dec 1;27(8):e616-e621. doi: 10.1097/RHU.0000000000001418.